Evidence map›Paper›PMID 19117641›Full record

Trial reportNeurobiology of aging2010

Epigenetic changes in Alzheimer's disease: decrements in DNA methylation.

Diego Mastroeni, Andrew Grover, Elaine Delvaux, Charisse Whiteside, Paul D Coleman, Joseph Rogers

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neurobiology of aging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 4 syntheses or guidelines pooled it, 387 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Epigenetic changes in the progression of Alzheimer's disease.Mechanisms of ageing and development · 2013
    Trial
  6. Review
  7. Co-expression network multivariate regression.Briefings in bioinformatics · 2026
    Article
  8. Review
  9. Article
  10. Long-read sequencing reveals genomic and epigenomic variation in the dark genome of human Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. DNA Methylation in Alzheimer's Disease.Current topics in behavioral neurosciences · 2025
    Review
  20. Review

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Diego MastroeniL.J. Roberts Center for Alzheimer's Research, Sun Health Research Institute, P.O. Box 1278, Sun City, AZ 85372, USA.
Andrew Grover
Elaine Delvaux
Charisse Whiteside
Paul D Coleman
Joseph Rogers
Banner Sun Health Research Institute · US

Funding

PRESENCE AND ROLE OF IMMUNE MARKERS IN ALZHEIMER'S BRAINR01AG007367 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI ROGERS, JOSEPH B · 1988 to 2014
$3.3M
DNA methylation in Alzheimer?s disease and normally aged brainR01AG036400 · NIA · BANNER SUN HEALTH RESEARCH INSTITUTE · PI COLEMAN, PAUL D · 2009 to 2013
$2.0M
Alzheimer's disease: a blood diagnostic and biomarker of disease progressionR56AG007367 · NIA · BANNER SUN HEALTH RESEARCH INSTITUTE · PI ROGERS, JOSEPH B · 2010 to 2011
$594k
Peripheral Biomarkers in Familial Alzheimer's DiseaseR21AG030429 · NIA · BANNER SUN HEALTH RESEARCH INSTITUTE · PI COLEMAN, PAUL D · 2008 to 2009
$404k
NIA NIH HHS AG0-7367NIA NIH HHS R01 AG036400NIA NIH HHS R21 AG030429NIA NIH HHS R56 AG007367PHS HHS 030429
6 · The paper itself

Abstract

DNA methylation is a vital component of the epigenetic machinery that orchestrates changes in multiple genes and helps regulate gene expression in all known vertebrates. We evaluated immunoreactivity for two markers of DNA methylation and eight methylation maintenance factors in entorhinal cortex layer II, a region exhibiting substantial Alzheimer's disease (AD) pathology in which expression changes have been reported for a wide variety of genes. We show, for the first time, neuronal immunoreactivity for all 10 of the epigenetic markers and factors, with highly significant decrements in AD cases. These decrements were particularly marked in PHF1/PS396 immunoreactive, neurofibrillary tangle-bearing neurons. In addition, two of the DNA methylation maintenance factors, DNMT1 and MBD2, have been reported also to interact with ribosomal RNAs and ribosome synthesis. Consistent with these findings, DNMT1 and MBD2, as well as p66α, exhibited punctate cytoplasmic immunoreactivity that co-localized with the ribosome markers RPL26 and 5.8s rRNA in ND neurons. By contrast, AD neurons generally lacked such staining, and there was a qualitative decrease in RPL26 and 5.8s rRNA immunoreactivity. Collectively, these findings suggest epigenetic dysfunction in AD-vulnerable neurons.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseDNA MethylationDown-RegulationEpigenesis, GeneticFemaleGenetic MarkersGenomic InstabilityHumansImmunohistochemistryMaleMiddle AgedNeuronsGenetic Markers

Identifiers

PMID19117641
PMCPMC2962691
OpenAlexW1982354720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.